MovDisordV3, Ncbi, Merge, bibRecord, 004136

Effects of levodopa on regional cerebral metabolism and blood flow.

Identifieur interne : 004136 ( Ncbi/Merge ); précédent : 004135; suivant : 004137

Effects of levodopa on regional cerebral metabolism and blood flow.

Auteurs : Ji Hyun Ko [États-Unis] ; Renata P. Lerner ; David Eidelberg

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.

RBID : pubmed:25296957

English descriptors

KwdEn :
- Animals, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Cerebral Cortex (blood supply), Cerebral Cortex (drug effects), Cerebral Cortex (metabolism), Cognition Disorders (drug therapy), Cognition Disorders (etiology), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Neuroimaging, Parkinson Disease (complications), Parkinson Disease (drug therapy), Regional Blood Flow (drug effects).
MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- blood supply : Cerebral Cortex.
- complications : Parkinson Disease.
- drug effects : Cerebral Cortex, Regional Blood Flow.
- drug therapy : Cognition Disorders, Parkinson Disease.
- etiology : Cognition Disorders.
- metabolism : Cerebral Cortex.
- Animals, Humans, Neuroimaging.

Abstract

Levodopa (L-dopa) has been at the forefront of antiparkinsonian therapy for a half century. Recent advances in functional brain imaging have contributed substantially to the understanding of the effects of L-dopa and other dopaminergic treatment on the activity of abnormal motor and cognitive brain circuits in Parkinson's disease patients. Progress has also been made in understanding the functional pathology of dyskinesias, a common side effect of l-dopa treatment, at both regional and network levels. Here, we review these studies, focusing mainly on the new mechanistic insights provided by metabolic brain imaging and network analysis.

DOI: 10.1002/mds.26041
PubMed: 25296957

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000367
to stream PubMed, to step Curation: 000367
to stream PubMed, to step Checkpoint: 000250

Links to Exploration step

pubmed:25296957

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of levodopa on regional cerebral metabolism and blood flow.</title>
<author><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji Hyun" last="Ko">Ji Hyun Ko</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lerner, Renata P" sort="Lerner, Renata P" uniqKey="Lerner R" first="Renata P" last="Lerner">Renata P. Lerner</name>
</author>
<author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25296957</idno>
<idno type="pmid">25296957</idno>
<idno type="doi">10.1002/mds.26041</idno>
<idno type="wicri:Area/PubMed/Corpus">000367</idno>
<idno type="wicri:Area/PubMed/Curation">000367</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000250</idno>
<idno type="wicri:Area/Ncbi/Merge">004136</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of levodopa on regional cerebral metabolism and blood flow.</title>
<author><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji Hyun" last="Ko">Ji Hyun Ko</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lerner, Renata P" sort="Lerner, Renata P" uniqKey="Lerner R" first="Renata P" last="Lerner">Renata P. Lerner</name>
</author>
<author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cerebral Cortex (blood supply)</term>
<term>Cerebral Cortex (drug effects)</term>
<term>Cerebral Cortex (metabolism)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Humans</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Neuroimaging</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Regional Blood Flow (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Cerebral Cortex</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebral Cortex</term>
<term>Regional Blood Flow</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cerebral Cortex</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Neuroimaging</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa (L-dopa) has been at the forefront of antiparkinsonian therapy for a half century. Recent advances in functional brain imaging have contributed substantially to the understanding of the effects of L-dopa and other dopaminergic treatment on the activity of abnormal motor and cognitive brain circuits in Parkinson's disease patients. Progress has also been made in understanding the functional pathology of dyskinesias, a common side effect of l-dopa treatment, at both regional and network levels. Here, we review these studies, focusing mainly on the new mechanistic insights provided by metabolic brain imaging and network analysis.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25296957</PMID>
<DateCreated><Year>2015</Year>
<Month>02</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>02</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>1</Issue>
<PubDate><Year>2015</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of levodopa on regional cerebral metabolism and blood flow.</ArticleTitle>
<Pagination><MedlinePgn>54-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26041</ELocationID>
<Abstract><AbstractText>Levodopa (L-dopa) has been at the forefront of antiparkinsonian therapy for a half century. Recent advances in functional brain imaging have contributed substantially to the understanding of the effects of L-dopa and other dopaminergic treatment on the activity of abnormal motor and cognitive brain circuits in Parkinson's disease patients. Progress has also been made in understanding the functional pathology of dyskinesias, a common side effect of l-dopa treatment, at both regional and network levels. Here, we review these studies, focusing mainly on the new mechanistic insights provided by metabolic brain imaging and network analysis.</AbstractText>
<CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ko</LastName>
<ForeName>Ji Hyun</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lerner</LastName>
<ForeName>Renata P</ForeName>
<Initials>RP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Eidelberg</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P50 NS071675</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P50 NS071675</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>10</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2012 May 15;61(1):228-39</RefSource>
<PMID Version="1">22406356</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2007 Jan;64(1):20-4</RefSource>
<PMID Version="1">17210805</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2007 Mar;27(3):597-605</RefSource>
<PMID Version="1">16804550</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2007 Jul;130(Pt 7):1834-46</RefSource>
<PMID Version="1">17470495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2007 Nov;10(11):1369-76</RefSource>
<PMID Version="1">17965657</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19559-64</RefSource>
<PMID Version="1">18042721</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Oct;27(12):1484-92</RefSource>
<PMID Version="1">23038645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2012 Nov;72(5):635-47</RefSource>
<PMID Version="1">22941893</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2013 Mar 6;33(10):4540-9</RefSource>
<PMID Version="1">23467370</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Jun;19(6):622-7</RefSource>
<PMID Version="1">23529021</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2013 Sep;78:204-9</RefSource>
<PMID Version="1">23578575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Aug;28(9):1212-4</RefSource>
<PMID Version="1">23861327</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Neurol Neurosci Rep. 2013 Dec;13(12):411</RefSource>
<PMID Version="1">24136458</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2014 Feb 18;82(7):620-7</RefSource>
<PMID Version="1">24453082</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2014 Apr 15;90:15-23</RefSource>
<PMID Version="1">24269570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2014 May 6;82(18):1597-604</RefSource>
<PMID Version="1">24719485</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2014 Jun;75(6):829-36</RefSource>
<PMID Version="1">24889498</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cereb Cortex. 2014 Nov;24(11):2873-83</RefSource>
<PMID Version="1">23733911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2004 Dec;127(Pt 12):2747-54</RefSource>
<PMID Version="1">15329355</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Feb;123 ( Pt 2):394-403</RefSource>
<PMID Version="1">10648446</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2001 Mar;124(Pt 3):558-70</RefSource>
<PMID Version="1">11222456</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 2001 Jul;86(1):249-60</RefSource>
<PMID Version="1">11431506</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2001 Dec 11;57(11):2083-8</RefSource>
<PMID Version="1">11739830</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 Nov;16(6):1014-22</RefSource>
<PMID Version="1">11748732</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Aging. 2003 Mar-Apr;24(2):197-211</RefSource>
<PMID Version="1">12498954</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2003 Feb;126(Pt 2):451-61</RefSource>
<PMID Version="1">12538411</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2003 Dec;60(12):1745-8</RefSource>
<PMID Version="1">14676050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1965 Nov;15(11):980-4</RefSource>
<PMID Version="1">5892413</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1984 May;15(5):419-24</RefSource>
<PMID Version="1">6610384</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1990;5(3):203-13</RefSource>
<PMID Version="1">2117706</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Consult Clin Psychol. 1991 Feb;59(1):12-9</RefSource>
<PMID Version="1">2002127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1991;44(3):591-605</RefSource>
<PMID Version="1">1754053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Int Neuropsychol Soc. 2004 Oct;10(6):888-93</RefSource>
<PMID Version="1">15637779</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1204-10</RefSource>
<PMID Version="1">16107352</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2006 May 15;31(1):301-7</RefSource>
<PMID Version="1">16466936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2006 Sep 13;26(37):9448-61</RefSource>
<PMID Version="1">16971529</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2006 Oct;129(Pt 10):2667-78</RefSource>
<PMID Version="1">16844713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2006 Oct;99(2):381-92</RefSource>
<PMID Version="1">16942598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2007 Jan 15;34(2):714-23</RefSource>
<PMID Version="1">17113310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 1998 Aug;1(4):263-5</RefSource>
<PMID Version="1">10195155</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 1998 Aug;1(4):286-9</RefSource>
<PMID Version="1">10195161</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dtsch Med Wochenschr. 1962 Sep 7;87:1807-10</RefSource>
<PMID Version="1">14448985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuron. 2008 Jan 24;57(2):178-201</RefSource>
<PMID Version="1">18215617</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2008 Apr 15;70(16 Pt 2):1470-7</RefSource>
<PMID Version="1">18367705</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2008 Apr 16;28(16):4201-9</RefSource>
<PMID Version="1">18417699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 May;131(Pt 5):1373-80</RefSource>
<PMID Version="1">18400841</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2009 Jan 23;158(2):693-704</RefSource>
<PMID Version="1">18722512</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosurg. 2009 Jun;110(6):1278-82</RefSource>
<PMID Version="1">19301972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2009;4(7):e6154</RefSource>
<PMID Version="1">19584921</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2009 Sep;35(3):348-51</RefSource>
<PMID Version="1">19501164</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2009 Oct;32(10):548-57</RefSource>
<PMID Version="1">19765835</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2009 Nov;34(12):2477-88</RefSource>
<PMID Version="1">19606087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Nov 17;73(20):1670-6</RefSource>
<PMID Version="1">19917989</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 2010 Jan;31(1):88-97</RefSource>
<PMID Version="1">19585587</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2010 Jan;257(1):72-8</RefSource>
<PMID Version="1">19662326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2010 Jan;30(1):2-14</RefSource>
<PMID Version="1">19738630</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2010 Jan 20;30(3):1049-56</RefSource>
<PMID Version="1">20089913</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2010 Mar;30(3):505-9</RefSource>
<PMID Version="1">20051975</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2010 Mar;112(6):1465-76</RefSource>
<PMID Version="1">20050978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2011 Jan 15;54(2):1244-53</RefSource>
<PMID Version="1">20851193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2011 Jun 15;69(12):e113-25</RefSource>
<PMID Version="1">21531388</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 Aug;134(Pt 8):2339-57</RefSource>
<PMID Version="1">21771855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2011 Aug 30;77(9):858-65</RefSource>
<PMID Version="1">21849641</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Aging. 2012 Jan;33(1):206.e29-39</RefSource>
<PMID Version="1">20961661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 2012 Apr;32(4):633-42</RefSource>
<PMID Version="1">22126913</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D002540">Cerebral Cortex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000098">blood supply</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D059906">Neuroimaging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012039">Regional Blood Flow</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS628503 [Available on 01/01/16]</OtherID>
<OtherID Source="NLM">PMC4314428 [Available on 01/01/16]</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blood flow</Keyword>
<Keyword MajorTopicYN="N">dopamine</Keyword>
<Keyword MajorTopicYN="N">levodopa</Keyword>
<Keyword MajorTopicYN="N">metabolism</Keyword>
<Keyword MajorTopicYN="N">positron emission tomography (PET)</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>8</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>9</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year>
<Month>10</Month>
<Day>9</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pmc-release"><Year>2016</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25296957</ArticleId>
<ArticleId IdType="doi">10.1002/mds.26041</ArticleId>
<ArticleId IdType="pmc">PMC4314428</ArticleId>
<ArticleId IdType="mid">NIHMS628503</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
<name sortKey="Lerner, Renata P" sort="Lerner, Renata P" uniqKey="Lerner R" first="Renata P" last="Lerner">Renata P. Lerner</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Ko, Ji Hyun" sort="Ko, Ji Hyun" uniqKey="Ko J" first="Ji Hyun" last="Ko">Ji Hyun Ko</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004136 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004136 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:25296957
   |texte=   Effects of levodopa on regional cerebral metabolism and blood flow.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:25296957" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effects of levodopa on regional cerebral metabolism and blood flow.

Effects of levodopa on regional cerebral metabolism and blood flow.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki